文献速递白血病

吉瑞替尼对比挽救性化疗在 predominantly Asian 复发/难治性 FLT3 突变急性髓系白血病患者中的 3 期研究

Phase 3 study of gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia.
PubMed 文献 · Leukemia · 2024-09-05

COMMODORE 3 期试验在 predominant Asian 复发/难治性 FLT3 突变急性髓系白血病患者中比较吉瑞替尼与挽救性化疗,主要终点总生存期在吉瑞替尼组显著更长(9.6 个月 vs 5.0 个月;HR 0.566,95%CI 0.392–0.818,p=0.00211),无事件生存期也显著更长(2.8 个月 vs 0.6 个月;HR 0.551,95%CI 0.395–0.769,p=0.00004),验证了 ADMIRAL 试验的结果。

要点

  • 吉瑞替尼组中位总生存期 9.6 个月,挽救性化疗组 5.0 个月(HR 0.566,p=0.00211)。
  • 吉瑞替尼组中位无事件生存期 2.8 个月,挽救性化疗组 0.6 个月(HR 0.551,p=0.00004)。
  • 吉瑞替尼组复合完全缓解率 50.0%,挽救性化疗组 20.3%。

核心结论

  • COMMODORE 试验表明,在 predominantly Asian 复发/难治性 FLT3 突变急性髓系白血病患者中,吉瑞替尼显著改善总生存期和无事件生存期,验证了 ADMIRAL 试验中吉瑞替尼的结果。

研究设计与样本

  • 3 期 COMMODORE 试验,在 predominantly Asian 复发/难治性 FLT3 突变急性髓系白血病患者中比较吉瑞替尼与挽救性化疗。
  • 截至 2020 年 6 月 30 日(研究启动后 32.2 个月的中期分析),共随机 234 例患者(吉瑞替尼组 n=116;挽救性化疗组 n=118)。
  • 主要终点为总生存期;次要终点包括无事件生存期和完全缓解率。

主要发现

  • 吉瑞替尼组中位总生存期 9.6 个月 vs 挽救性化疗组 5.0 个月(HR 0.566,95%CI 0.392–0.818,p=0.00211),中位随访 10.3 个月。
  • 吉瑞替尼组中位无事件生存期 2.8 个月 vs 挽救性化疗组 0.6 个月(HR 0.551,95%CI 0.395–0.769,p=0.00004)。
  • 吉瑞替尼组完全缓解率 16.4% vs 挽救性化疗组 10.2%;复合完全缓解率分别为 50.0% vs 20.3%。
  • 经暴露校正的 ≥3 级不良事件发生率吉瑞替尼组为 58.38 事件/患者年,挽救性化疗组为 168.30 事件/患者年。
  • 吉瑞替尼常见不良事件为贫血(77.9%)和血小板减少(45.1%);吉瑞替尼血浆浓度在给药后约 4 小时达峰,多次给药后约 3 倍蓄积。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The phase 3 COMMODORE trial evaluated gilteritinib versus salvage chemotherapy (SC) in a predominantly Asian relapsed/refractory (R/R) FLT3-mutated (FLT3mut+) acute myeloid leukemia (AML) patient population. The primary endpoint was overall survival (OS); secondary endpoints included event-free survival (EFS) and complete remission (CR) rate. As of June 30, 2020 (interim analysis: 32.2 months after study initiation), 234 patients were randomized (gilteritinib, n = 116; SC, n = 118). Median OS was significantly longer with gilteritinib versus SC (9.6 vs. 5.0 months; HR 0.566 [95% CI: 0.392, 0.818]; p = 0.00211) with a median follow-up of 10.3 months. Median EFS was also significantly longer with gilteritinib (2.8 vs. 0.6 months; HR 0.551 [95% CI: 0.395, 0.769]; p = 0.00004). CR rates with gilteritinib and SC were 16.4% and 10.2%, respectively; composite CR rates were 50.0% and 20.3%, respectively. Exposure-adjusted grade ≥3 adverse event (AE) rates were lower with gilteritinib (58.38 events/patient-year [E/PY]) versus SC (168.30 E/PY). Common AEs with gilteritinib were anemia (77.9%) and thrombocytopenia (45.1%). Gilteritinib plasma concentration peaked ~4 h postdose; ~3-fold accumulation occurred with multiple dosing. The COMMODORE trial demonstrated that gilteritinib significantly improved OS and EFS in predominantly Asian patients, validating the outcomes of gilteritinib from the ADMIRAL trial in R/R FLT3mut+ AML.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Wang J, Jiang B, Li J, et al. Phase 3 study of gilteritinib versus salvage chemotherapy in predominantly Asian patients with relapsed/refractory FLT3-mutated acute myeloid leukemia. Leukemia. 2024. PMID: 39237634. doi:10.1038/s41375-024-02382-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。